DiagnaMed Launches Division For Generative AI Healthcare Applications

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

A new division has been established by DiagnaMed Holdings (CSE: DMED) to focus on the development and commercialization of generative AI. Referred to as Health GenAI, the division is set to host a suite of products driven by GPT-4.

The goal of Health GenAI is to support the healthcare market in improving patient outcomes, efficiency, and operational workflow via a suite of programs powered by artificial intelligence. DiagnaMed has indicated it intends to launch at least three products from the new division this year alone.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

“We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI™, our generative AI brain health platform,” stated CEO Fabio Chianelli of the announcement.

WATCH: DiagnaMed Brings AI To Brain Health — With Fabio Chianelli And Dr. John Kounios

The recently announced FormGPT, which is described as a generative AI data collection and analysis tool for the healthcare industry, is to be housed under the new division. The product enables professionals in the healthcare space to create customized forms and surveys to collect relevant patient data, provide pre-and-post visit treatment feedback, monitor patient progress, and to analyze results.

DiagnaMed’s CERVAI meanwhile will be housed under a separate division. CERVAI is the firms generative AI brain health platform, which lead to the development of FormGPT.

DiagnaMed last traded at $0.095 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

This Copper Mine Costs 1/6 to Restart | SSR Mining X Roxmore

Why Cambria Hit Pause on Its Massive Copper-Gold Spinout

Can Gold Rescue Washington From Its Debt Trap? | Andy Schectman – Miles Franklin

Recommended

Mercado Minerals Lengthens El Triunfo Vein by 190 Metres, Readies 1,500-Metre Zamora Drill Program

Blue Jay Gold Signs Ocean Partners Deal to Ship Steller Stockpiles Through 2027

Related News

DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada

DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health...
Tuesday, March 12, 2024, 09:19:18 AM

DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023

DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI...
Wednesday, September 13, 2023, 09:58:53 AM

DiagnaMed Anticipates CERVAI Commercial Launch In Q4 2023

DiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation...
Tuesday, June 20, 2023, 10:05:29 AM

DiagnaMed Sees Brain Age AI Platform Validated In Peer-Reviewed Paper

DiagnaMed Holdings (CSE: DMED) is reporting this morning that its flagship Brain Age Brain Health...
Thursday, April 25, 2024, 09:30:26 AM

DiagnaMed Launches Brain Age Brain Health AI Tool In Canada

DiagnaMed Holdings (CSE: DMED) has officially launched its Brain Age Brain Health AI solution in...
Tuesday, April 23, 2024, 09:22:20 AM